Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07312162 · ClinicalTrials.gov registry record
Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots
A clinical trial of Hepatocellular Carcinoma, sponsored by University of Southern California.
- Recruiting
- Registry status
- 730
- Enrollment target
- 1
- Study location
NCT07312162: Recruiting study of Hepatocellular Carcinoma, sponsored by University of Southern California.
NCT07312162 is a study of Hepatocellular Carcinoma that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 730 participants, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (190% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07312162, a study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- 730 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates barriers to early detection of liver cancer.
Primary Outcome
Patient social determinants of health-related needs will be measured through a health questionnaire created for the study. The patient can respond yes or no to having a lack of transportation to and from appointments. The patient is given a scale of never true, sometimes true and often true for questions regarding food insecurity. The patient can indicate that they do or do not have housing today (or choose not to answer), and they can indicate how many times they moved in the last year as 0, 1,
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
California
- USC / Norris Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2027-12-31 |
What NCT07312162 shows while recruiting
NCT07312162 is an observational study that tracks outcomes without assigning an intervention. The registered 730 participants enrollment target is mid-sized for trials with a published cap, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (190% higher).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT07312162 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07312162 about?
NCT07312162 is a clinical study titled "Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots". This study evaluates barriers to early detection of liver cancer.
What is the current status of trial NCT07312162?
This trial is currently recruiting. The enrollment target is 730 participants. The study started on 2022-01-01. Estimated completion is 2027-12-31.
What conditions does trial NCT07312162 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT07312162?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT07312162?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07312162 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07312162's enrollment target sits among peer trials
730 16th of 145 higher than 130 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- NCT05739123 · 728 participants
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI